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A B S T R A C T
The purpose of this study was to evaluate the effect of process (homogenization speed and
evaporation time) and formulation (aqueous/organic phase ratio, surfactant concentra-
tion, polymer type and concentration, and drug amount) variables on the preparation of
paclitaxel-loaded biodegradable polymeric nanoparticles using modified solvent evapora-
tion technique.Thereafter, a formulation was selected and subjected to evaluation of inclusion
of a co-surfactant for further reduction of particle size. Particle size, encapsulation effi-
ciency and in-vitro drug release kinetics were evaluated. It was observed that the inclusion
of vitamin E TPGS (0.01%), Poloxamer 188 (0.5%) or Tween 80 (0.25%) reduced the particle
size of nanoparticles to 230, 244 or 301 nm from 438 nm, respectively. Encapsulation effi-
ciency increased for both vitamin E TPGS and Poloxamer 188 up to concentration at 0.010%
and 0.25%, respectively, while this was not the case for Tween 80. Comparison of drug release
kinetics demonstrated that drug release accelerated from paclitaxel-loaded biodegradable
nanoparticles prepared with the inclusion of Tween 80 but was delayed for Poloxamer 188
and vitamin E TPGS.Thus, it was concluded that the particle size of the nanoparticles could
be reduced further and the paclitaxel release kinetics could easily be adjusted by taking
advantage by the inclusion of a co-surfactant.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Recent years have seen significant effort devoted to formu-
late therapeutic agents in biocompatible nanocomposites such
as nanoparticles, nanocapsules, micellar systems and conju-
gates as drug delivery systems. Application of nanotechnology
for diagnosis, monitoring, disease therapy, and control of bio-
logical systems was referred to as “nanomedicine”, and it has
been receiving extensive attention over the past decade [1].
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Among these drug delivery systems, nanoparticles have re-
ceived a considerable attention for the delivery of wide variety
of drugs as well as biological macromolecules and vaccines [2].
Nanoparticles have been defined as submicron sized drug car-
riers, where the drug is either adsorbed on the surface or
encapsulated within the particle [3]. These nanoparticles can
be prepared from natural and synthetic polymers that may or
may not be biodegradable depending on their route of admin-
istration. Biodegradable polymeric nanoparticles administered
intravenously have been successfully used to control and target
drug to specific site of action at the therapeutically optimal rate.
Owing to the size in nanometric range, these biodegradable
nanoparticles have a potential to escape the reticulo-endothelial
system and thus an increase in the residence time is seen with
these drug delivery systems [4]. Nanoparticles can also over-
come the multiple drug resistance phenotype mediated by
glycoprotein-P (P-gP) [5], resulting in an increased drug content
inside the cells and because of this reason biodegradable
nanoparticles have been widely studied for P-gP substrates like
paclitaxel [6].
Paclitaxel is a taxane originally derived from the bark of the
Pacific yew tree Taxus brevifolia and has shown to exhibit a sig-
nificant activity against a variety of solid tumors including
breast cancer, advanced ovarian carcinoma, lung cancer and
neck carcinomas [7]. However, the successful clinical applica-
tion is mainly restricted by its high hydrophobicity and limited
availability. Due to its low solubility in water and other phar-
maceutical solvents acceptable for parenteral administration,
Taxol (Bristol-Myers Squibb, New York, NY) is marketed as a
co-solvent system of Cremophor EL and dehydrated alcohol
at a 50:50 (v/v) ratio. These co-solvents have been reported to
have serious side effects such as hypersensitivity, nephrotox-
icity and neurotoxicity as well as physical instability and
incompatibility with common polyvinyl chloride (PVC) intra-
venous administration sets [8]. In order to eliminate the
Cremophor based vehicle and in an attempt to increase the
therapeutic efficacy, biodegradable polymeric nanoparticles have
been widely studied [9,10].
Poly-lactide (PLA) and poly-lactide-co-glycolide (PLGA) are
the most widely used biodegradable polymers because hydro-
lysis of these leads to monomers (i.e., lactic and glycolic acid)
which are endogenous and are metabolized by the body via
Kreb’s cycle resulting in minimal systemic toxicity [11].The deg-
radation of these polymers varies from several days to several
months depending on the molecular weight and co-polymer
composition, which increases patient compliance [12]. Biode-
gradable polymeric nanoparticles are usually prepared either
by anionic polymerization of monomers or by dispersion of
the dissolved polymers to give nanoparticles via various
methods, such as solvent evaporation/extraction, spontane-
ous emulsification/solvent diffusion, salting out/emulsification-
diffusion, and supercritical technology [13]. In solvent
evaporation method, the polymer is dissolved or dispersed in
an organic solvent (e.g., dichloromethane, chloroform or ethyl
acetate), which is then emulsified in an aqueous solution using
different surfactants to form stable oil-in-water emulsion. High
shear homogenization or sonication is used for emulsifica-
tion.The organic phase is then allowed to evaporate resulting
in a suspension of nanoparticles. The nanoparticles are later
recovered by filtration or lyophilization. Various process
variables, such as homogenization speed and solvent evapo-
ration time, as well as formulation parameters, such as organic
and disperse phase ratio, polymer type and concentration, sur-
factant type and concentration, and drug amount, can influence
the characteristics of nanoparticles prepared by solvent
evaporation/extraction method.
A surfactant is used to reduce the surface tension and sta-
bilize the droplet phase during emulsification process. Different
types of surfactants, such as ionic surfactants and non-ionic
polymer surfactants, may be used to stabilize the oil-in-
water emulsions [14]. Selection of the surfactant is critical to
obtain particles in nanometric range. The type and concen-
tration of surfactant are not only important in stabilizing
emulsions during microemulsion process, but also helpful in
preventing aggregation of the droplets, thus maintaining a low
polydispersity index. Biocompatibility and toxicity of the sur-
factants are also important considerations for pharmaceutical
application. Most researchers have fabricated nanoparticles
using a single surfactant in varying concentrations. The role
of a surfactant in the system is to reduce the interfacial tension
between oil and water. Sometimes it is not possible for a sur-
factant to reduce surface tension to a required level either
because of its properties or due to low concentration. If,
however, a second amphiphile is added to the system, the effect
of both surfactants may be additive provided that the adsorp-
tion of one surfactant on the surface of nanodroplets does not
affect that of the other and also the mixed micelle formation
does not reduce the available concentration of surfactant mol-
ecules. The second amphiphile, referred to as co-surfactant,
need not necessarily be capable of forming association struc-
tures of its own [14]. The inclusion of a co-surfactant may also
reduce the amount of the surfactant needed, thus avoiding the
potential toxicity issue due to the larger amount of the indi-
vidual surfactant needed for preparing the formulation. The
effect of a mixture of surfactant and co-surfactant has not been
researched in detail and only limited literature is available in
this regard [15]. Combination of surfactant and co-surfactant
may be beneficial by altering the physicochemical properties
of the nanoparticles. Therefore, the effects of various process
as well as formulation variables were carried out first to iden-
tify, in terms of small particle size and high encapsulation
efficiency, a suitable formulation which was then subjected to
the study of effect of inclusion of a co-surfactant on particle
size, encapsulation efficiency and in-vitro drug release kinet-
ics from paclitaxel-loaded biodegradable polymeric
nanoparticles prepared by the modified solvent evaporation
technique.
2. Materials and methods
2.1. Materials
Paclitaxel was obtained from LC Laboratories (Woburn, MA).
Poly-vinyl alcohol (PVA, MW 146,000–186,000), poly (L-lactide)
(PLA,MW 75,000), poly (D,L-lactide-co-glycolide) (PLGA 50:50,MW
75,000 and 5000 as well as PLGA 75:25, MW 75,000 and 5000),
D-α-tocopherol polyethylene glycol succinate (vitamin ETPGS),
and Tween 80 were supplied by Sigma-Aldrich (St. Louis, MO).
Poloxamer 188 was purchased from Spectrum Chemicals and
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Laboratory Products (Gardena, CA). All other chemicals and sol-
vents were of analytical grade and used as received without
further purification or treatment.
2.2. Analytical methodology
Paclitaxel was determined based on the reported literature with
modification to avoid any interference from solvents used in
this investigation [16]. Briefly, the method employed a reverse
phase HPLC (Hewlett Packard HP 1100 series) with Waters
Spherisorb ODS1 Column (5 μm, 4.6 mm × 250 mm) and a
mixture of 47% v/v acetonitrile, 20% v/v methanol and 33% v/v
distilled water as the mobile phase. Fifty microliters of stan-
dard drug solutions or sample solutions were injected.The flow
rate was 2 ml/min and paclitaxel was detected at 254 nm with
a retention time of 2.9 min. A standard plot of paclitaxel was
generated over the concentration range of 0.5–500 μg/ml and
was found to be linear with r2 value of 0.9997.
2.3. Preparation of paclitaxel-loaded biodegradable
polymeric nanoparticles
The preparation of paclitaxel-loaded nanoparticles was based
on oil/water emulsification solvent evaporation method. Both
polymer and the drug were dissolved in dichloromethane as
organic solvent. The organic phase so formed was added drop
wise to an aqueous phase, containing PVA as surfactant, using
a high-speed microprocessor (Virtis Tempest I.Q. 2 Homog-
enizer, Sentry Microprocessor, Kent City, MI). The emulsion
formed wasmagnetically stirred to evaporate dichloromethane.
After evaporation of the solvent, the nanoparticles were re-
covered by ultracentrifugation (Beckman Coulter Ultracentrifuge/
Beckman Coulter Inc., Brea, CA) at ~40,000 g for 30 min. The
pellet obtained was re-suspended in distilled water and cen-
trifuged again. The washing step was repeated twice and the
pellet obtained was lyophilized for 8 h using Labconco Shell
Freeze Dry Equipment (Labconco Corporation, Kansas City, MO)
to obtain free flowing powder.
2.4. Evaluation of process and formulation variables
In a typical emulsification-solvent evaporation process, various
process and formulation variables govern the physicochemi-
cal properties of nanoparticles (e.g., particle size, encapsulation
efficiency and drug release kinetics). Effects of process vari-
ables (i.e., homogenization speed and evaporation time) on the
preparation of paclitaxel-loaded biodegradable polymeric
nanoparticles were studied first in this investigation. After the
selection of homogenization speed and evaporation time for
small particles size and high encapsulation efficiency of
nanoparticles, five formulation variables (i.e., aqueous/organic
phase ratio, surfactant concentration, polymer type and con-
centration, and drug amount) were evaluated for further
optimization of the formulation (Table 1). Only one variable was
Table 1 – Effect of formulation variables on the preparation of paclitaxel-loaded biodegradable polymeric nanoparticles.
Formulation
code
Aqueous/organic phase
ratio (v/v)
Surfactanta
concentration (% w/v)
Polymer
type
Polymer concentration
(% w/v)
Drug amount
(mg)
Effect of aqueous/organic phase ratio
A1 1:1 (50%)c 0.25 PLGA 50:50 10 2
A2 2:1 (33.3%)c 0.25 PLGA 50:50 10 2
A3b 4:1 (20%)c 0.25 PLGA 50:50 10 2
A4 8:1 (11.1%)c 0.25 PLGA 50:50 10 2
A5 12:1 (7.7%)c 0.25 PLGA 50:50 10 2
Effect of surfactant concentration
B1 4:1 0.10 PLGA 50:50 10 2
B2b 4:1 0.25 PLGA 50:50 10 2
B3 4:1 0.50 PLGA 50:50 10 2
B4 4:1 0.75 PLGA 50:50 10 2
B5 4:1 1.0 PLGA 50:50 10 2
B6 4:1 2.0 PLGA 50:50 10 2
Effect of polymer type
C1b 4:1 0.25 PLGA 50:50 10 2
C2 4:1 0.25 PLGA 75:25 10 2
C3 4:1 0.25 PLA 10 2
Effect of polymer concentration
D1b 4:1 0.25 PLGA 50:50 10 2
D2 4:1 0.25 PLGA 50:50 15 2
D3 4:1 0.25 PLGA 50:50 20 2
Effect of drug amount
E1 4:1 0.25 PLGA 50:50 10 1
E2b 4:1 0.25 PLGA 50:50 10 2
E3 4:1 0.25 PLGA 50:50 10 3
E4 4:1 0.25 PLGA 50:50 10 4
E5 4:1 0.25 PLGA 50:50 10 5
a Polyvinyl alcohol (PVA) was used as surfactant.
b Same formulation variables.
c Concentration of organic phase.
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studied at a time while keeping all other variables and geom-
etry of the fabrication system constant.
2.4.1. Effect of homogenization speed
Energy density, which is energy applied per unit total volume
has a direct effect on droplet size of the emulsion produced
[17]. Since the magnitude of shear stress is inversely related
to the droplet size of the emulsion, increasing the shear stress
may result in reduced droplet size to produce nanodroplets.
Therefore, emulsification was performed at different homog-
enization speeds of 1000, 5000, 10,000 or 15,000 rpm for 15 min
with evaporation time of organic phase set at 12 h.
2.4.2. Effect of evaporation time
During solvent evaporation, the nanodroplets are solidified to
produce nanoparticles and the drug is adsorbed on the surface
and/or entrapped within the polymer matrix of these
nanoparticles. Also, during the transition of nanodroplets to
form nanoparticles, the drug may have a tendency to diffuse
out into the external aqueous phase. Thus, it is important to
control the solidification rate of the nanodroplets in order to
achieve small particle size and high encapsulation efficiency.
The evaporation of the organic phase was carried out for 3, 6
or 12 h with constant magnetic stirring.
2.4.3. Effect of aqueous/organic phase ratio
Since change in the aqueous/organic phase ratio may result
in change in the viscosity of the system, which in turn can
change the characteristics of the nanoparticles (e.g., particle
size, encapsulation efficiency, surface morphology, etc.), there-
fore, various aqueous/organic phase ratios (i.e., 1:1, 2:1, 4:1, 8:1
and 12:1) were evaluated.
2.4.4. Effect of surfactant concentration
The effect of surfactant concentration was studied because the
presence of surfactant at the aqueous/organic phase inter-
face governs the effectiveness of formation of emulsion and
stabilization of the oil nanodroplets during the emulsifica-
tion solvent evaporation process. Based on the preliminary
experiments, poly-vinyl alcohol was selected as surfactant and
concentration at 0.1, 0.25, 0.50, 0.75, 1.0 or 2% w/v was studied.
2.4.5. Effect of polymer type
Lactide and glycolide content of the biodegradable polymers
affects the degradation rate of the polymeric nanoparticles and
consequently the impact on drug release kinetics. Thus, three
different polymers of the same biodegradable class viz PLA (MW
75,000), PLGA (75:25, MW 75,000) and PLGA (50:50, MW 75,000)
were used.
2.4.6. Effect of polymer concentration
Increased amount of hydrophobic polymer may result in en-
capsulation of hydrophobic drug to a greater extent. Hence,
PLGA (50:50, MW 75,000) was studied in three different con-
centrations of 10%, 15% and 20%.
2.4.7. Effect of drug amount
To achieve maximum encapsulation, variable amount of drug,
ranging from 1 mg to 5 mg, was added to the organic phase
to evaluate the effect of drug amount in the nanoparticles.
2.5. Evaluation of the inclusion of a co-surfactant
Upon understanding the effects of various process as well as
formulation variables on the preparation of paclitaxel-loaded
biodegradable polymeric nanoparticles, a suitable formula-
tion, in terms of small particle size and high encapsulation
efficiency, was selected for further experiments to study the
effect of inclusion of a co-surfactant. By keeping all other for-
mulation and process variables constant, vitamin E TPGS at
concentrations of 0.005%, 0.010%, 0.025% or 0.050%, Poloxamer
188 at concentrations of 0.10%, 0.25%, 0.50%, 0.75%, or 1.0% and
Tween 80 at concentrations of 0.05%, 0.10%, 0.25%, 0.50% or 1.0%,
respectively, were evaluated.
2.6. Characterization of paclitaxel-loaded biodegradable
polymeric nanoparticles
Following the preparation of paclitaxel-loaded biodegradable
polymeric nanoparticles, particle size analysis, determina-
tion of encapsulation efficiency and in-vitro drug release kinetics
were performed to evaluate their characteristics. All experi-
ments were conducted in triplicate.
2.6.1. Particle size analysis
The mean particle diameter and polydispersity index was de-
termined by photon correlation spectroscopy using Delsa Nano
Series Zeta Potential and Submicron Particle Size Analyzer (Brea,
CA).The analysis was performed at room temperature at a scat-
tering angle of 90°.
2.6.2. Determination of encapsulation efficiency
The encapsulation efficiency was determined by dissolving
10 mg of lyophilized nanoparticles in 2 ml of dichloromethane
and then mixed with 3 mL of acetonitrile:water (50:50 v/v).The
solution was vortexed vigorously and dichloromethane was
evaporated under a nitrogen stream until a clear solution was
obtained. The final solution was diluted to 5 ml with
acetonitrile:water (50:50 v/v) and analyzed using the HPLC
method described previously. Drug encapsulation efficiency was
expressed as the percentage of drug in the fabricated
nanoparticles with respect to the initial amount of drug used
for the preparation of nanoparticles.
Encapsulation efficiency
Amount of drug in the nanoparticles
(%)
,
=
mg
Total amount of drug initially added mg,
× 100
2.6.3. In-vitro drug release kinetics
The in-vitro drug release kinetics were carried out by suspend-
ing 20 mg of the paclitaxel-loaded nanoparticles in 10 ml of
phosphate buffered saline solution (PBS, pH 7.4) containing 0.1%
v/v ofTween 80. Screw capped glass tubes were used to conduct
the in-vitro release studies.The glass tubes were shaken at 37 °C
in Forma Scientific water shaker bath (Asheville, NC) at 120
cycles/min. Samples (2 ml each) were collected from each bottle
at predetermined time intervals for at least 15 d and up to 24 d.
The tubes were centrifuged at ~14,000 g for 15 min before
sampling and the same volume of fresh PBS was replaced
into the release bottles immediately after each sampling of the
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supernatant. The supernatant was analyzed for drug content
by the HPLC method described previously.
3. Results and discussion
3.1. Characterization of paclitaxel-loaded biodegradable
polymeric nanoparticles
The comparisons of particle size, encapsulation efficiency, and
cumulative amount of drug released from paclitaxel-loaded bio-
degradable polymeric nanoparticles prepared using various
process and formulation variables are summarized in Table 2.
3.1.1. Effect of homogenization speed
Nanoparticles prepared at lower homogenization speeds (1000,
5000, and 10,000 rpm, formulations X1, X2, and X3) resulted in
larger particle size (913 nm, 856 nm, and 899 nm, respectively),
as compared to 15,000 rpm (formulation X4) for which the
particle size was 438 nm (Table 2). Emulsification at high speed
would result in the reduction of emulsion globules and con-
sequently, reduction of the emulsion globule size allowed the
formation of smaller size of nanoparticles. With the higher
speed of homogenization,more energy is released in the process
that leads to a rapid dispersion of polymeric organic phase and
because of which nanoparticles of small size and monomodal
distribution are obtained. A bimodal distribution was seen in
case of lower homogenization speeds at 1000 and 5000 rpm,
which may be due to insufficient dispersion of the organic
phase. On the other hand, above 15,000 rpm, it was difficult
to control the process in terms of formation of froth and air
bubbles.
The encapsulation efficiency increased from 65.3% to 77.5%
when the speed of emulsification was increased from 1000 rpm
(formulation X1) to 15,000 rpm (formulation X4). Although not
linear, the increase in encapsulation efficiency was greater when
homogenization speed was increased from 10,000 rpm to
15,000 rpm (72.1% to 77.5%) than when the homogenization
Table 2 – Comparison of particle size, encapsulation efficiency, and cumulative amount of drug released from paclitaxel-
loaded biodegradable polymeric nanoparticles prepared using various process and formulation variables.
Formulation code Particle size
(nm ± SD)a
Mean polydispersity
index
Encapsulation efficiency
(% ± SD)a
Cumulative drug released
at 15 d (% ± SD)a
Effect of homogenization speed (rpm)
X1 (1000) 913 ± 55 0.75 65.3 ± 1.9 –
X2 (5000) 856 ± 103 0.28 67.1 ± 1.8 19.7 ± 0.5
X3 (10,000) 899 ± 114 0.24 72.1 ± 2.1 23.9 ± 0.4
X4b (15,000) 438 ± 7 0.19 77.5 ± 2.1 34.5 ± 1.4
Effect of evaporation time (h)
Y1b (12) 438 ± 7 0.19 77.5 ± 2.1 34.5 ± 1.4
Y2 (6) 607 ± 71 0.28 49.6 ± 3.7 27.2 ± 1.2
Y3 (3) 752 ± 109 0.32 34.7 ± 2.8 17.8 ± 1.3
Effect of aqueous/organic phase ratio
A1 (1:1) 614 ± 25 0.25 84.0 ± 3.7 45.4 ± 1.3
A2 (2:1) 534 ± 43 0.23 81.4 ± 3.7 40.4 ± 1.1
A3b (4:1) 438 ± 7 0.19 77.5 ± 2.1 34.5 ± 1.4
A4 (8:1) 503 ± 38 0.37 76.0 ± 3.0 25.5 ± 0.5
A5 (12:1) 704 ± 75 0.28 74.6 ± 0.04 21.7 ± 0.6
Effect of surfactant concentration (% w/v)
B1 (0.10) 489 ± 66 0.17 65.8 ± 0.8 –
B2b (0.25) 438 ± 7 0.19 77.5 ± 2.1 34.5 ± 1.4
B3 (0.50) 481 ± 12 0.28 79.4 ± 5.1 35.5 ± 0.8
B4 (0.75) 641 ± 51 0.29 63.1 ± 2.7 31.5 ± 0.8
B5 (1.0) 777 ± 58 0.27 65.3 ± 4.0 25.9 ± 1.0
B6 (2.0) 1265 ± 133 0.23 58.6 ± 1.7 –
Effect of polymer type
C1b (PLGA 50:50) 438 ± 7 0.19 77.5 ± 2.1 34.5 ± 1.4
C2 (PLGA 75:25) 558 ± 23 0.25 79.9 ± 1.8 34.1 ± 0.6
C3 (PLA) 458 ± 17 0.24 86.2 ± 1.5 24.9 ± 1.1
Effect of polymer concentration (% w/v)
D1b (10) 438 ± 7 0.19 77.5 ± 2.1 34.5 ± 1.4
D2 (15) 672 ± 45 0.26 85.0 ± 0.7 21.6 ± 1.7
D3 (20) 1053 ± 130 0.43 94.3 ± 3.2 10.9 ± 0.5
Effect of drug amount (mg)
E1 (1) 439 ± 27 0.23 93.9 ± 1.2 12.6 ± 1.7
E2b (2) 438 ± 7 0.19 77.5 ± 2.1 34.5 ± 1.4
E3 (3) 625 ± 28 0.27 74.9 ± 1.7 35.4 ± 0.7
E4 (4) 658 ± 31 0.27 72.5 ± 3.2 34.4 ± 0.6
E5 (5) 639 ± 13 0.21 76.6 ± 14.4 –
a Data represent mean ± standard deviation, n = 3.
b Same process variables as well as formulation variables.
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speed was increased from 5000 rpm to 10,000 rpm (67.1% to
72.1%).The increase in encapsulation efficiency may have been
due to the fact that a unidirectional and less turbulent flow
in the case of lower speed may have resulted in the loss of drug
from the organic phase.
The cumulative amount of drug released at 15 d increased
with increasing homogenization speed. Owing to a large par-
ticle size and low yield resulting from low homogenization
speed, formulation X1 was not evaluated for drug release.The
difference in the release profiles can be attributed to the dif-
ference in the particle size of the nanoparticles (Fig. 1a). The
difference in the mean particle size of formulations X2 and X3
was very small (856 nm versus 899 nm) and so was the cu-
mulative amount of drug released at 15 d (67.1% versus 72.1%).
The mean particle size of formulation X4 was less than 50%
(i.e., 438 nm) the particle size of formulations X2 and X3, and
the difference in cumulative amount of drug released from for-
mulation X4 was high (34.5% versus 19.7% and 23.9%). Larger
particles exhibited slower rate of release of the drug, due to
the longer diffusion pathways that the drug had to travel to
reach dissolution medium.
3.1.2. Effect of evaporation time
As shown in Table 2, an increase in the evaporation time re-
sulted in a decrease in particle size, increase in encapsulation
efficiency, and decrease in cumulative amount of drug re-
leased at the end of the experiment. A critical parameter
determining the particle size is diffusion of organic solvent
through the interface of emulsion droplets [17].When evapo-
ration is carried out for a shorter period of time (i.e., faster
evaporation rate), the diffusion of the organic solvent out of
oil droplets may not have been complete before the droplets
start to harden, thus resulting in larger particles. On the other
hand, when the organic solvent is allowed to evaporate for a
longer time, the extent of diffusion of organic solvent out of
the droplets is greater and results in smaller particle size. During
the organic solvent evaporation process, there is a gradual de-
crease of the dispersion volume and consequently an increase
of the viscosity of the dispersed droplets. This may have af-
fected the droplet size equilibrium, involving the processes of
droplet coalescence and agglomeration during the early step
of the organic solvent removal.
Reduced encapsulation efficiency in the case of shorter
evaporation time may be due to the rapid replacement of the
organic solvent with the aqueous medium before the droplet
hardening occurs.As concluded previously, smaller particle size
of nanoparticles is a factor for the faster drug release from the
nanoparticles. It was observed that smaller particle size of for-
mulation X4 provides an increased surface area for dissolution
contributing to a greater release. Furthermore, it has been re-
ported that rapid solvent evaporation leads to a smoother
surface of the particles as compared to the particles ob-
tained by delayed solvent evaporation [18].Thus, the smoother
surface of the polymer matrix could have resulted in much
slower release (Fig. 1b).
Based on the results obtained, process variables of formu-
lation X4 was selected and used for the evaluation of various
formulation variables described below.
3.1.3. Effect of aqueous/organic phase ratio
The particle size of nanoparticles exhibited an initial de-
crease from 704 nm to 438 nm when the concentration of the
organic phase was increased from 7.7% (formulation A5) to 20%
(formulation A3). On further increasing the concentration from
20% to 50% (formulation A1), the particle size increased from
438 nm to 614 nm (Table 2). These findings may be explained
on the basis of change in the viscosity of the emulsion formed
during processing. Increased viscosity of the emulsion by al-
ternation of aqueous/organic phase ratio resulted in high
viscous resistance against the shear force during the forming
of nanodroplets [19]. The external energy in the form of ho-
mogenization and the amount of emulsifier causing droplet
breakdown were kept constant; thus on increasing the aqueous
phase volume, the same amount of energy must now be dis-
tributed in the large volume, leading to less droplet breakdown,
and hence bigger nanoparticles were obtained.
The encapsulation efficiency was within a narrow range of
74.6% (formulation A5) and 84.0% (formulation A1). Higher en-
capsulation efficiency of formulations A1 and A2 may be
because of increased viscosity of the emulsion formed which
would have resulted in high viscous resistance against the shear
force during the emulsification. Upon increasing the aqueous
phase volume, the amount of drug dissolved in the aqueous
phase increases and, therefore, increasing the drug loss form
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Fig. 1 – Effect of (a) homogenization speed and (b)
evaporation time on in-vitro drug release kinetics of
paclitaxel-loaded biodegradable polymeric nanoparticles
(data represent mean ± standard deviation, n = 3).
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organic phase results in the reduction of the encapsulation
efficiency [17].
The cumulative amount of drug released at 15 d increased
with increasing concentration of organic phase used in the
preparation of nanoparticles (Table 2). The difference in the
release profiles (Fig. 2a) can be attributed to the difference in
the surface of nanoparticles regardless of the difference of par-
ticle size. It has been reported that large amount of aqueous
phase results in faster precipitation of the polymer with a
smoother and less porous surface of the nanoparticles [20].
The porosity decreases with increasing aqueous/organic
phase ratio and thus lower aqueous/organic phase ratio could
have resulted in more porous nanoparticles leading to faster
release rates [21]. Furthermore, the burst release at lower
aqueous/organic phase ratios can probably be explained by the
difference in the distribution of drug in nanoparticles due to
different evaporation rates of the organic solvent. The solu-
bility of dichloromethane in water is considered low. At lower
aqueous/organic phase ratio (formulation A1), dichloromethane
will distribute into the aqueous phase slowly, which is con-
trolled by dichloromethane evaporation rate; therefore, the drug
will tend to migrate onto the nanoparticle surface together with
dichloromethane because of more solubility in the organic
solvent, resulting in drug-rich nanoparticle surface.When the
aqueous/organic phase ratio is high (formulation A5),
dichloromethane distributes in water quickly and the drug so-
lidifies in the polymer matrix rapidly.The drug near the surface
will diffuse out of the nanoparticle first, causing burst release.
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Fig. 2 – Effect of (a) aqueous/organic phase ratio, (b) surfactant concentration, (c) polymer type, (d) polymer concentration,
and (e) drug amount on in-vitro drug release kinetics of paclitaxel-loaded biodegradable polymeric nanoparticles (data
represent mean ± standard deviation, n = 3).
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These findings are in agreement with the published research
where the effect of process and formulation variables on the
internal morphology of PLGAmicroparticles was evaluated [22].
3.1.4. Effect of surfactant concentration
In this investigation, PVA was selected and used as the sur-
factant. It was observed that at 0.10% PVA concentration
(formulation B1), the emulsion formed was not stable and phase
separation occurred after a few hours of emulsification result-
ing in the formation of polymer aggregates. Increasing PVA
concentration from 0.10% to 0.25% (formulation B2) and 0.50%
(formulation B3) resulted in particle sizes of 438 nm and 481 nm,
respectively. Increase in particle size from 481 nm to 1265 nm
was seen with further increase in concentration from 0.50%
to 2.0% (formulation B6). An increase in PLGA nanoparticle size
with increase in PVA concentration has also been reported in
the literature [23]. In the emulsion solvent evaporation method,
the emulsification and stabilization of the globules are two
crucial factors. The amount of surfactant plays an important
role, because it can avoid the coalescence of the oil globules.
The surfactantmolecules tend to align themselves at the droplet
surface lowering the free energy at the interface between two
phases and resisting coalescence of the droplets. Smaller
nanodroplets have large surface area and thus need more sur-
factant to stabilize the emulsion nanodroplets. Less amount
of surfactant may result in formation of unstable emulsion im-
plying that 0.1% PVA may not be sufficient to stabilize the
emulsion nanodroplets, leading to phase separation after a few
hours.
The encapsulation efficiency increased from 65.8% to 79.4%
and then reduced to 58.6% when the surfactant concentra-
tion increased from 0.10% (formulation B1) to 0.50% (formulation
B3) and further to 2.0% (formulation B6), respectively. De-
crease in encapsulation efficiency of the drug from 79.4% to
58.6% was seen with increasing surfactant concentration.
Paclitaxel being a hydrophobic molecule will tend to stay in
the oil nanodroplets. But with an increase in PVA concentra-
tion in the external aqueous phase, paclitaxel may diffuse out
from the oil nanodroplets and solubilize as micelles in the
aqueous phase. More solubilization of the drug in the exter-
nal aqueous phase will result in decreased amount of surfactant
available at the aqueous/organic phase interface and thus ag-
glomeration of nanodroplets may take place. A secondary
explanation could be on the basis of gelatinization of PVAmol-
ecules. Due to strong hydrogen bonds via hydroxyl group
between inter- or intra-molecules of PVA, gelatinization of PVA
at the oil/water interface may occur during the nanoparticle
formation process [24]. As a result, increasing particle size and
decreasing encapsulation efficiency were observed with in-
creasing surfactant concentration.
The cumulative amount of drug released at surfactant con-
centrations of 0.25%, 0.50%, 0.75% and 1.0% (formulations B2-
B5) were 34.5%, 35.5%, 31.5% and 25.9%, respectively (Table 2).
Although the drug release profiles demonstrated slower release
with increasing surfactant concentration, the release of drug
from formulations B2 and B3 prepared containing 0.25% and
0.50% PVA were essentially similar (Fig. 2b).The amount of drug
released decreased with an increase in the surfactant concen-
tration.This phenomenon could be attributed to the difference
in particle size at different concentrations. As the surfactant
concentration increased from 0.25% to 1.0%, the particle size
increased from 438 nm to 777 nm.The increase in surface area
due to smaller size could have been contributing to a greater
release. Burst release amount decreased with increasing sur-
factant concentration. Similar findings have been reported [25].
The surfactant concentration at 0.10% level resulted in an un-
stable emulsion, a flake like mass was obtained after freeze-
drying and hence formulation B1 was not characterized for drug
release. In addition, due to particle size in micron range, for-
mulation B6 was also not characterized for drug release.
3.1.5. Effect of polymer type
Themean particle size of the nanoparticles prepared using PLGA
50:50, PLGA 75:25, and PLA (formulations C1-C3) were 438 nm,
558 nm, and 458 nm, respectively (Table 2). The particle size
of nanoparticles formulated with these three different poly-
mers was almost similar despite the difference in their lactide
content. These results indicate that the type of polymer did
not influence the particle size of the nanoparticles.This finding
is in agreement with a previous study using PLA and PLGA poly-
mers to prepare oral microparticles for budesonide delivery to
ileum and colon [26]. The similarity in particle size can be at-
tributed to the fact that both polymers used belong to the same
class of biodegradable polymers exhibiting the same inher-
ent viscosity (0.9 dl/g).
The encapsulation efficiency was found to be dependent on
the solid-state solubility of drug in the polymer.The mean en-
capsulation efficiencies of the nanoparticles prepared using
PLGA 50:50, PLGA 75:25 and PLA (formulations C1–C3) were
77.5%, 79.9% and 86.2%, respectively. The encapsulation effi-
ciency for nanoparticles formulated with PLGA 75:25 and PLGA
50:50 were almost similar, despite the difference in their lactide
content. One possibility may be that the change in lactide
content of the polymer from 75% to 50% does not signifi-
cantly affect the properties of nanoparticles. In the case of PLA,
because the lactide:glycolide ratio is increased from 50% to
100%, the hydrophobic interaction of the lipophilic drug with
PLGA is increased, thus resulting in higher encapsulation ef-
ficiency [27].
The cumulative amount of drug released at 15 d was es-
sentially similar between formulation C1 and formulation C2
(34.5% versus 34.1%) while a much lower value (24.9%) was ob-
served for formulation C3 (Table 2). From the drug release
profiles shown in Fig. 2c, formulations C1 and C2 incorpo-
rated with PLGA 50:50 and PLGA 75:25, respectively, resulted
in higher release than that of formulation C3 (PLA). In-vitro
release of the drug from nanoparticles has been reported to
have an inverse relationship with the solid-state drug-polymer
solubility [28]. Higher percentage of drug was released from the
nanoparticles formulated with PLGA 50:50 and PLGA 75:25, since
the polymers exhibiting lower solid-state drug solubility as com-
pared to PLA with high solid-state drug solubility. Moreover,
PLA is crystalline polymer while PLGA is amorphous. Due to
the rigid structure of the nanoparticles prepared using crys-
talline PLA, the diffusion of the drug is reduced [26]. The
glycolide content determines the hydrophilicity and degrada-
tion of the polymers. PLGA is more hydrophilic with a faster
degradation rates as compared to PLA which lacks any gly-
colic acid and hence more hydrophobic in nature, resulting in
a much slower degradation rate [29]. Additionally, the drug
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release from nanoparticles formulated using PLGA 50:50 and
PLGA 75:25 had similar release properties despite the differ-
ence in their lactide content. There is a possibility that the
change in the lactide content does not significantly affect the
properties of nanoparticles [10].
3.1.6. Effect of polymer concentration
The mean particle size of formulations prepared using 10%,
15%, or 20% (formulations D1-D3) of PLGA 50:50 resulted in
438 nm, 672 nm and 1053 nm, respectively (Table 2). A bimodal
size distribution was seen in the case of polymer concentra-
tions of 15% and 20%. As the polymer concentration increased
from 10% to 15% and 20%, the mean encapsulation efficiency
increased from 77.5% to 79.9% and 86.2%, respectively.The cu-
mulative amount of drug released at 15 d from formulations
D1–D3 with polymer concentrations of 10%, 15% and 20% were
35.5%, 21.6% and 10.9%, respectively. The drug release de-
creased with increase in the polymer concentration as seen
in Fig. 2d and suggested that polymer concentration play a sig-
nificant role in determining the drug release from the paclitaxel-
loaded PLGA 50:50 nanoparticles.
Increasing the polymer concentration, while keeping the
volume of organic phase constant at 10 ml, the viscosity of the
organic phase is increased, which results in increase in the
viscous forces resisting droplet breakdown and thus bigger oil
droplets are formed, resulting in increased particle size [23].
Similarly the increase in polymer concentration increases the
organic phase viscosity, which increases the diffusional resis-
tance to drug molecules from organic phase to the aqueous
phase, thereby entrapping more drug in the polymer
nanoparticles. Increasing polymer concentration also in-
creases particle size and drug content is known to increase with
particle size in other systems [30]. An increase in particle size
increases the length of diffusional pathways into the aqueous
phase, thereby reducing the drug loss through diffusion and
increasing the drug content.Also, the time required for polymer
precipitation decreases at higher polymer concentration, so
there is less time for drug molecules to diffuse out of
nanoparticles, which increases the drug content [27]. Another
reason could be the availability of a greater amount of polymer
to encapsulate the drug, thus not causing saturation of en-
capsulation [26].The decreased percentage of cumulative drug
released could be due to the increased particle size and thus
smaller surface area at higher polymer concentration. Another
explanation for lower cumulative amount of drug release at
higher polymer concentration could be the increased concen-
tration of the polymer present which hinders the drug release
by diffusion [26].
3.1.7. Effect of drug amount
Themean particle size of formulations E1 and E2 prepared using
1 mg or 2 mg of drug was about 440 nm (Table 2), but the par-
ticle size increased to above 600 nm when the amount of drug
was increased to 3 mg, 4 mg, or 5 mg (formulations E3–E5).The
increase in particle size can be attributed to the increased
content of drug present in the emulsion nanodroplets. These
results are in agreement with the previously published study
where a 50% increase in particle size was observed when the
drug concentration was increased from 0.2% to 1.0% [26].
Because only a fixed amount of drug can be incorporated in
a given amount of the polymer, it would appear that further
increase in amount of drugmay have resulted in amore viscous
dispersed phase resulting in larger particles [22].
The encapsulation efficiency exhibited a slight downward
trend (from about 94% to about 77%) with increasing amount
of drug in the formulation. The drug content in the
nanoparticles is affected by the drug–polymer interactions and
the drug miscibility in the polymer [28]. Higher drug miscibil-
ity leads to higher drug incorporation. Almost constant
encapsulation efficiency was seen in this study, which might
be due to a fixed amount of polymer available in the formu-
lation to encapsulate the drug. Thus it can be implied that
amount of drug does not play a very pivotal role in influenc-
ing the encapsulation efficiency of paclitaxel-loaded PLGA
nanoparticles as long as the amount of polymer is kept con-
stant. Studies show that the internal micro-morphology of the
microparticles is not affected by increase in drug loading [22].
It was observed that the cumulative amount of drug re-
leased at 15 d from the formulations containing 1 mg, 2 mg,
3 mg or 4 mg of drug were 12.6%, 34.5%, 35.4% and 34.4%, re-
spectively (Table 2). The rate of drug release was slower when
the drug content was 1 mg (formulation E1), and faster when
the amount of drug was increased (Fig. 2e). The slower rate of
release as well as cumulative amount released at 15 d may be
attributed to relatively higher proportion of polymer in the for-
mulation that hindered diffusion of drug from the nanoparticles.
These results indicate that at higher drug content, drug release
is independent of amount of drug present in the formula-
tion. Hence, it was assumed that formulation E5 with 5 mg drug
will also show a similar pattern and, therefore, formulation E5
was not characterized for drug release.
3.2. Evaluation of the inclusion of a co-surfactant
Although the release of paclitaxel from the biodegradable
nanoparticles is mainly attributed to the degradation of polymer,
particle size of nanoparticle is another important factor on the
drug release.Therefore, the inclusion of a co-surfactant might
help in the formation of smaller droplets of microemulsion by
reducing the surface tension and subsequently might affect
the drug release from nanoparticles formed. Therefore, upon
understanding the effects of various process as well as for-
mulation variables on the preparation of paclitaxel-loaded
biodegradable nanoparticles, formulation A3 was selected for
further experiments to study the effect of inclusion of a
co-surfactant.
Ten different non-ionic surfactants, namely, Poloxamer 188,
vitamin E TPGS, Tween 80, polyethylene glycol 2000, di-
palmitoylphosphatidylcholine, Poloxamer 407, Pluronic 127,
lecithin, dextran and cholesterol were investigated as the co-
surfactant coupled with 0.25% PVA (formulation A3) as the
surfactant at three different concentrations (data not shown).
Only three of these, namely, Poloxamer 188, vitamin E TPGS,
and Tween 80, were able to reduce the particle size less than
that obtained with PVA alone (i.e., 438 nm) and hence were con-
sidered for further experiments to study the effect of inclusion
of these co-surfactants at various concentration levels.The com-
parisons of particle size, encapsulation efficiency, and
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cumulative amount of drug released form these experiments
are summarized in Table 3.
3.2.1. Particle size
It was observed that the particle sizes of the formulations I2–
I5 having vitamin E TPGS at concentration of 0.005%, 0.010%,
0.025% and 0.050% were 1296 nm, 230 nm, 248 nm and 290 nm,
respectively (Table 3). There was a reduction of almost 200 nm
form 438 nm (formulation I1) when vitamin E TPGS was used
as the co-surfactant with PVA. At low concentration of 0.005%,
a bimodal distribution of the particles was seen with wider stan-
dard deviation. For formulations I3 and I4, the monomers of
vitamin E TPGS may have aligned on the oil/water interface
along with PVA to cover the oil nanodroplets more efficiently
and thus reducing the interfacial tension between the oil and
water phase and resulting in lower particles size. Similar results
have been reported when vitamin E TPGS was used as emul-
sifier to prepare paclitaxel:PLGA nanoparticles [10].
When Poloxamer 188 was used as the co-surfactant, the par-
ticle size decreased from 438 nm (no co-surfactant) to 362 nm,
300 nm, and 244 nm at concentrations of 0.10%, 0.25%, and
0.50% (formulations J2–J4), respectively, but further increase in
concentration to 0.75% and 1.0% (formulations J5 and J6) re-
sulted in increase in particle size. It has been known that
increasing the viscosity of water exerts the stabilizing effect
of Poloxamer 188.The sufficiently high viscosity prevents emul-
sified multiple nanodroplets from interflowing. Poloxamer 188,
as a non-ionic emulsifier, has been reported to act as a co-
emulsifier during the emulsification process, resulting in smaller
particle size and narrower size distribution [31]. An interac-
tion between Poloxamer 188 and polyester linkage of PLGA in
methylene chloride solution has been emphasized by an
associative thickening effect [32]. The hydrophobic propylene
chain of Poloxamer 188, like vitamin ETPGS, may have aligned
on the oil/water interface along with PVA to cover the oil
nanodroplets more efficiently and thus reducing the interfa-
cial tension between the oil and water phase and resulting in
lower particles size. But, as the concentration of poloxamer 188
was increased, the hydrophilic chains of one particle may have
interacted with hydrophilic chains of the other particle and this
inter-particle interaction of chains may have resulted in ag-
glomeration at higher concentrations.
The effect of Tween 80 on the particle size was essentially
similar to that of Poloxamer 188. Increase in the concentra-
tion of Tween 80 exhibited an initial decrease in particle size
followed by an increase in particle size with increasing con-
centration of Tween 80. This could be due to the alignment of
the hydrophobic monooleate part on the oil/water interface
along with PVA to cover the oil nanodroplets more efficiently
and thus reducing the interfacial tension between the oil and
water phase and resulting in lower particle size.
3.2.2. Encapsulation efficiency
The encapsulation efficiency ranged between 71.7% (formu-
lation I5) and 81.6% (formulation I3) when vitamin E TPGS was
used as the co-surfactant. The encapsulation efficiency in-
creased at low vitamin E TPGS concentrations (0.005% and
0.010%), then exhibited a decline with increasing concentra-
tion to 0.050%. This can be explained on the basis of critical
micellar concentration (CMC) value of TPGS.The reported CMC
value of vitamin E TPGS is 0.025% [10]. Initially there is an in-
crease in the encapsulation that may be due to enhanced
stabilization of the oil nanodroplets due to co-surfactant that
may have prevented the leaching out of the drug from the oil
Table 3 – Comparison of particle size, encapsulation efficiency, and cumulative amount of drug released from
formulation A3 with the inclusion of a co-surfactant.
Formulation
code
Co-surfactant
concentration
(% w/v)
Particle size
(nm ± SD)a
Mean
polydispersity
index
Encapsulation
efficiency
(% ± SD)a
Cumulative drug
released at 24 d
(% ± SD)a
Vitamin E TPGS
I1b 0 438 ± 7 0.19 77.5 ± 2.1 48.3 ± 9.2
I2 0.005 1296 ± 87 0.36 78.7 ± 2.6 –
I3 0.010 230 ± 16 0.37 81.6 ± 1.1 37.6 ± 2.5
I4 0.025 248 ± 11 0.26 77.5 ± 1.6 33.3 ± 2.0
I5 0.050 290 ± 20 0.28 71.7 ± 3.8 –
Poloxamer 188
J1b 0 438 ± 7 0.19 77.5 ± 2.1 48.3 ± 9.2
J2 0.10 362 ± 45 0.29 77.7 ± 1.2 –
J3 0.25 300 ± 17 0.24 80.0 ± 2.2 35.7 ± 2.2
J4 0.50 244 ± 10 0.28 77.8 ± 0.6 35.0 ± 2.1
J5 0.75 345 ± 36 0.23 75.4 ± 2.6 –
J6 1.0 431 ± 34 0.29 75.5 ± 3.6 –
Tween 80
K1b 0 438 ± 7 0.19 77.5 ± 2.1 48.3 ± 9.2
K2 0.05 389 ± 19 0.39 74.9 ± 1.4 –
K3 0.10 355 ± 25 0.31 41.1 ± 1.9 64.6 ± 2.4
K4 0.25 301 ± 18 0.27 34.1 ± 3.1 60.9 ± 3.6
K5 0.50 377 ± 22 0.30 28.3 ± 2.2 –
K6 1.0 422 ± 21 0.28 17.1 ± 2.8 –
a Data represent mean ± standard deviation, n = 3.
b Same process variables and formulation variables as formulation A3.
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nanodroplets. As the concentration is slowly increased, more
and more monomers of vitamin E TPGS leaving the oil/water
interface tend to form micelles in the aqueous phase. As the
number of monomers decrease at the interface leaving the oil
nanodroplet surface more exposed to aqueous phase, drug may
have leached out of the oil nanodroplets, thus reducing en-
capsulation efficiency.
Poloxamer 188 had essentially no effect on the encapsula-
tion efficiency.The hydrophobic propylene chain of Poloxamer
188 may have aligned on the oil/water interface along with PVA
to cover the oil nanodroplets more efficiently, thus sterically
stabilizing the oil nanodroplets. As all the nanodroplets were
stabilized by the presence of surfactant and co-surfactant on
the interface, drug may not partition out to the aqueous phase
and hence no change in the encapsulation efficiency was seen.
The encapsulation efficiency in the presence of Tween 80
decreased with increasing concentration of Tween 80.The en-
capsulation efficiency of nanoparticles without co-surfactant
was 77.5% (formulation K1) which was reduced to 41.1% and
34.1% (formulations K3 and K4) with a co-surfactant concen-
tration of 0.10% and 0.25%, respectively. Similar to vitamin E
TPGS, this behavior could be explained on the basis of the CMC
value of Tween 80. The reported CMC value of Tween 80 is
0.0014% [33] and is known to form core shell cylinder mi-
celles in aqueous solutions [34]. As the concentration of Tween
80 is slowly increased, more and more monomers similar to
vitamin E TPGS, many monomers of Tween 80 leave the oil/
water interface and formmicelles.As the number of monomers
decrease at the interface leaving the oil droplet surface more
exposed to aqueous phase, drug may have diffused out of the
oil nanodroplets, thus reducing encapsulation efficiency.
3.2.3. In-vitro drug release kinetics
As the inclusion of a co-surfactant was to further reduce the
particle size of nanoparticles, in-vitro drug release kinetics from
formulations with smallest particle size were performed and
is represented in Fig. 3. It can be seen that drug release is ac-
celerated in case of Tween 80 (formulations K3 and K4), but is
delayed in case of vitamin E TPGS (formulations I3 and I4) and
Poloxamer 188 (formulations J3 and J4).Vitamin ETPGS has re-
cently been established as an emulsifier that possesses a dual
nature similar to an amphiphile [10].Although the exact portion
of the hydrophilic polar head and the lipophilic alkyl tail is not
elucidated, it is assumed that the polyethylene glycol portion
behaves as the polar head and the tocopherol succinate portion
behaves as the lipophilic tail. The cumulative amount of drug
released at 24 d from the formulations I3 and I4 with 0.01%
and 0.025% vitamin E TPGS were 37.6% and 33.3%, respec-
tively, which were less as compared to the formulation I1
(48.3%).This retarded drug release may be due to complete dis-
tribution of the vitamin E TPGS on the surface of the
nanoparticle. It has been reported via X-ray photoelectron mi-
croscopy that the surface of the nanoparticles fabricated using
vitamin E TPGS as emulsifier is independent of the type of
polymer used and the emulsifier surrounds the nanoparticle
surface completely [10].
Poloxamer 188, a triblock polymer of polypropylene oxide
and polyethylene oxide, when used as the co-surfactant retards
the release of the drug from formulations J3 and J4 as com-
pared to formulation I1. The cumulative amount of drug
released at 24 d from the formulations J3 and J4 with 0.25% and
0.50% of Poloxamer 188 at 24 d were found to be 35.7% and
35.0%, respectively. The drug release was independent of the
concentration of Poloxamer 188 used. Various hydrolytic pro-
cesses are involved in the degradation of PLGA, which leads
to the formation of acidic oligomers and monomers because
of which an acidic microenvironment is generated to facili-
tate the degradation process and thus more drug is released.
Poloxamers and poloxamines could possibly retard the deg-
radation by neutralizing the acidity generated during the
polymer degradation and could also prevent unwanted inter-
actions between the drug and the PLGA resulting in controlled
release of drug form polymer matrix [35]. It has also been re-
ported that the stability by poloxamer is due to steric
mechanism produced by the free hydrophilic polyethylene
chains.These free chains may interact with the free PVA chains
to further stabilize the nanoparticles and retard the release of
the drug [35].
The cumulative amount of drug released at 24 d from the
formulations K3 and K4 with 0.10% and 0.25% Tween 80 were
64.6% and 60.9%, respectively. The drug release profiles were
also found to be sensitive to co-surfactant concentration.A burst
effect was seen in both formulations K3 and K4 that could be
due to the presence of the drug onto or near the nanoparticle
surface. The HLB value of Tween 80 is 15 because of which it
has a strong tendency to form oil-in-water emulsion and thus
Tween 80maymigrate at oil/water interface along with the drug,
thereby increasing the drug concentration at the surface of the
nanoparticles [36].The repulsion exerted by monooleate group
of Tween 80 may have been counterbalanced by the hydrocar-
bon chains of PVA. Another possible reason for a faster release
of drug may be the smaller particle size of 355 nm and 301 nm
for formulations K3 and K4, respectively. Increased surface area
for dissolution may be contributing to a greater release.
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Fig. 3 – Effect of inclusion of a co-surfactant on in-vitro
drug release kinetics of paclitaxel-loaded biodegradable
polymeric nanoparticles (formulation A3) (data represent
mean ± standard deviation, n = 3).
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4. Conclusion
The results of this investigation elucidates that the process and
formulation variables could be effectively altered to achieve
the desired characteristics, such as particle size, entrapment
efficiency, and in vitro drug release kinetics, of paclitaxel-
loaded biodegradable polymeric nanoparticles. Additionally,
particle size of the nanoparticles could be reduced further and
the paclitaxel release kinetics could easily be adjusted by taking
advantage of synergistic action of surfactants by the inclu-
sion of a co-surfactant.
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